SciBX: Science-Business eXchange Contents: March 13 2014, Volume 7 / Issue 10

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS March 13 2014, Volume 7 / Issue 10 Analysis Cover Story Translational Notes Targets and Mechanisms Tools The Distillery: Therapeutics Cancer Endocrine/metabolic disease Hematology Infectious disease Musculoskeletal disease Neurology Other Pulmonary disease Renal disease The Distillery: Techniques Assays and screens Disease models Drug delivery Drug platforms Markers Advertisement BioPharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The November 2013 issue of BioPharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with NUMAB Drug Innovators   Analysis Cover Story Top Killer targets in metastasis Amy Donner doi:10.1038/scibx.2014.274 An international team has found a new pathway in NK cells that leads to the rejection of metastatic tumors. It remains unclear which components of the pathway will make the best targets. Full Text | PDF Translational Notes Top Repairing reproducibility C. Simone Fishburn doi:10.1038/scibx.2014.275 Although the NIH is taking steps to improve the reproducibility of preclinical data, many researchers are not waiting for guidelines and instead are angling to elevate standards at their own institutions. Full Text | PDF Targets and Mechanisms Top Zinc-ing about diabetes Kai-Jye Lou doi:10.1038/scibx.2014.276 ZNT8 burst onto the scene in 2007 as a promising diabetes target, and follow-up studies suggested that stimulating the zinc transporter protein could have therapeutic benefit. A new study suggests that the preferred approach might be to inhibit the target. Full Text | PDF Tools Top Hitchhiker's guide to the lymph node Benjamin Boettner doi:10.1038/scibx.2014.277 An MIT team has provided a recipe for delivering cancer vaccines to lymph nodes by tethering them to albumin. In proof-of-concept studies in mice, lymph node–targeted tumor antigens and adjuvants elicited strong immune responses and reduced tumor growth. Full Text | PDF Distillery: Therapeutics Cancer Top DNA (cytosine-5-)-methyltransferase 3α (DNMT3A) doi:10.1038/scibx.2014.278 In vitro and mouse studies suggest eliminating DNMT3A-mutant preleukemia cells could help prevent AML. Full Text | PDF Myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX); multiple endocrine neoplasia I (MEN1; menin) doi:10.1038/scibx.2014.279 SAR studies suggest compounds that disrupt the interaction between MLL and menin could be useful for treating some forms of AML and ALL. Full Text | PDF V-rel reticuloendotheliosis viral oncogene homolog A (RELA; p65); chromosome 11 open reading frame 95 (C11orf95) doi:10.1038/scibx.2014.280 Patient sample and cell culture studies suggest targeting a C11orf95-RELA fusion protein could help treat supratentorial ependymomas. Full Text | PDF Casitas B cell lymphoma-b (CBL-B); TYRO3 protein tyrosine kinase (TYRO3; SKY); AXL receptor tyrosine kinase (AXL; UFO); c-Mer proto-oncogene tyrosine kinase (MERTK) doi:10.1038/scibx.2014.281 In vitro and mouse studies suggest TYRO3, AXL and MERTK receptor (TAM receptor) inhibitors could help prevent metastasis by activating NK cells. Full Text | PDF IL-17A doi:10.1038/scibx.2014.282 Mouse studies suggest IL-17A inhibitors could help treat hepatocellular carcinoma (HCC). Full Text | PDF CREB binding protein (CREBBP; CBP); enhancer of zeste homolog 2 (EZH2); histone deacetylase (HDAC) doi:10.1038/scibx.2014.283 In vitro and mouse studies suggest HDAC or EZH2 inhibitors could help treat PTEN (MMAC1; TEP1)-deficient prostate cancers lacking CBP. Full Text | PDF E1A binding protein p300 (EP300; p300); PTEN (MMAC1; TEP1) doi:10.1038/scibx.2014.284 In vitro and mouse studies suggest inhibiting p300 could help treat PTEN-deficient prostate cancers. Full Text | PDF Endocrine/metabolic disease Top Solute carrier family 30 zinc transporter member 8 (SLC30A8; ZNT8) doi:10.1038/scibx.2014.285 Human genetic studies suggest inhibiting SLC30A8 could help prevent or treat type 2 diabetes. Full Text | PDF Hematology Top Activin receptor–like kinase 3 (ALK3) doi:10.1038/scibx.2014.286 Mouse studies suggest inhibiting the bone morphogenetic protein type I receptor ALK3 could help treat anemia. Full Text | PDF Infectious disease Top Quinolone resistance protein (NorA) doi:10.1038/scibx.2014.287 In vitro studies suggest boronic acid derivatives that inhibit the NorA bacterial efflux pump could help prevent antibiotic resistance. Full Text | PDF Musculoskeletal disease Top Sialic acid binding Ig-like lectin 15 (SIGLEC15) doi:10.1038/scibx.2014.288 Cell-based and mouse studies suggest inhibition of SIGLEC15 could help prevent osteoclast-mediated bone destruction in osteoporosis and other bone-loss disorders. Full Text | PDF Neurology Top Neurotensin (NTS) doi:10.1038/scibx.2014.289 In vitro and rodent studies suggest a conjugate of NTS and the brain-penetrating peptide Angiopep could help treat pain. Full Text | PDF Other Top Toll-like receptor 9 (TLR9) doi:10.1038/scibx.2014.290 In vitro, mouse and primate studies suggest a CpG DNA nanoparticle wrapped in the polysaccharide schizophyllan could be used as a vaccine adjuvant that activates B cells and plasmacytoid dendritic cells (pDCs). Full Text | PDF Pulmonary disease Top Thrombospondin-1 (TSP-1; THBS1) doi:10.1038/scibx.2014.291 In vitro and mouse studies suggest TSP-1 could help stimulate alveolar lung repair after injury. Full Text | PDF Renal disease Top Adenosine A3 receptor (ADORA3) doi:10.1038/scibx.2014.292 In vitro and cell-based studies identified an ADORA3 partial agonist that could help treat kidney disease caused by renal fibrosis. Full Text | PDF Distillery: Techniques Assays and screens Top Measurement of β-amyloid (Aβ) oligomers in cerebrospinal fluid (CSF) to diagnose and monitor the progression of Alzheimer's disease (AD) doi:10.1038/scibx.2014.293 An assay that measures Aβ oligomers levels in CSF could help diagnose AD and monitor disease progression in patients. Full Text | PDF Protein M, an IgG-binding protein with a new mode of antibody interaction doi:10.1038/scibx.2014.294 In vitro studies suggest Protein M, a broadly reactive, antibody-binding protein, could complement Proteins A and G as a reagent for large-scale antibody purification. Full Text | PDF Disease models Top Long-term, Plasmodium cynomolgi–infected primary hepatocyte culture to screen for malaria therapeutics doi:10.1038/scibx.2014.295 Long-term, P. cynomolgi–infected primary hepatocyte cultures could be used to identify therapeutics that prevent malaria relapse. Full Text | PDF Transcription activator–like effector nuclease (TALEN)-mediated genome editing to generate genetically modified monkeys doi:10.1038/scibx.2014.296 Primate studies suggest TALENs could be used to generate genetically modified monkeys to model disease. Full Text | PDF Transgenic mouse models of Netherton syndrome expressing human kallikrein-related peptidase 5 (KLK5) doi:10.1038/scibx.2014.297 Transgenic mice expressing human KLK5 in the epidermis could be used to study the biology of Netherton syndrome and screen for drugs to treat the indication. Full Text | PDF Drug delivery Top Drug-loaded, neutrophil-targeting nanoparticles to prevent inflammation-induced tissue damage doi:10.1038/scibx.2014.298 Neutrophil-targeting nanoparticles could help prevent tissue damage involving vascular inflammation. Full Text | PDF Drug platforms Top Gene catalog for differentiating human pluripotent stem cells (hPSCs) into mature, insulin-producing pancreatic β cells doi:10.1038/scibx.2014.299 In vitro and computational studies identified genes that could help develop strategies for β cell production from hPSCs. Full Text | PDF Lymph node–targeting cancer vaccines doi:10.1038/scibx.2014.300 Mouse studies suggest albumin-binding DNA and peptide vaccines could help stimulate antitumor immunity in lymph nodes to help treat cancer. Full Text | PDF Markers Top Injectable, synthetic markers for paper-based detection of disease in urine samples doi:10.1038/scibx.2014.301 Mouse studies suggest nanoparticles coated with protease-sensitive peptides that release biomarkers into urine can be used with paper-based assays to diagnose colorectal cancer and thrombosis. Full Text | PDF Top

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.